Meditation study examines blood levels of dopamine, glutamate and GABA

Meditation research just got a more biochemical lens: a Sri Lanka study measured blood levels of dopamine, glutamate, and GABA in long-term skilled meditators and found a pattern that hints at deeper physiological differences. The catch is just as important as the signal itself, because these were experienced practitioners, not beginners doing a few calm breaths, and blood markers can suggest association without proving a shortcut to better brain chemistry.

What this study actually measured

The study used a comparative analytical laboratory design and matched 30 long-term skilled meditators with 30 non-meditator controls. In the preprint version, venous blood was drawn from each participant and analyzed with ELISA, while the mean ages of the two groups were nearly identical, 42.23 years in meditators and 42.2 years in controls. That setup matters because it moves the discussion beyond self-report and into measurable biology, but it also keeps the results grounded in a very specific population.

The paper’s core question was simple and ambitious at the same time: do long-term meditators show different blood levels of neurotransmitters that are often tied to motivation, excitation, inhibition, and emotional regulation? By focusing on dopamine, glutamate, and gamma-aminobutyric acid, or GABA, the researchers joined a growing branch of contemplative science that is looking for objective markers rather than relying only on how relaxed people say they feel.

What changed in the blood

The biggest headline is that the meditators showed higher GABA and dopamine, while glutamate was lower. In the preprint data, GABA averaged 67.92 ng/ml in meditators versus 61.21 ng/ml in controls, with a p value of 0.006. Dopamine measured 134.8 ng/ml in meditators compared with 94.7 ng/ml in controls, with a p value of 0.019. Glutamate went in the opposite direction, at 6.0 ug/ml in meditators versus 7.3 ug/ml in controls, with a p value of 0.008.

Those numbers are intriguing because they line up with how mindfulness communities often talk about practice in functional terms. Dopamine is commonly linked with motivation and reward, glutamate with neural excitation, and GABA with inhibition and steadiness, so a pattern of higher dopamine and GABA alongside lower glutamate invites a closer look at how deep practice may relate to arousal and balance. Still, the study shows blood differences in a group of seasoned meditators, not a guaranteed effect of meditation for everyone.

Why blood markers matter, and where they stop

This is where the science gets exciting but also needs discipline. Blood-marker research can reveal biochemical correlates that are easier to measure than moment-to-moment brain states, and that makes it attractive in contemplative science, especially as researchers try to move toward more objective endpoints. The preprint’s conclusion even suggests meditation may have therapeutic relevance for neurological and neuropsychiatric disorders that involve neurotransmitter imbalance.

But blood markers are still a step removed from the lived experience of meditation and from the brain itself. A blood assay can show that two groups differ, yet it cannot by itself prove that a brief mindfulness course will raise dopamine, or that a specific change in the bloodstream maps cleanly onto a change in attention, compassion, or stress resilience. That is why the limitation in this story is not a footnote, it is the center of the interpretation.

How this fits into the wider meditation literature

The Sri Lanka paper sits inside a much broader scientific conversation that has already linked meditation and mindfulness to neuroplasticity, increased cortical thickness, reduced amygdala reactivity, improved brain connectivity, and changes in neurotransmitter levels. A 2024 systematic review in Biomedicines pushed that field further by calling for more diverse populations and more naturalistic settings, which makes this study’s Sri Lankan sample especially relevant.

The neurotransmitter focus also has a technical foundation. A 2015 review in Neuropsychology Review explained that modern 3T and higher MRI spectroscopy can quantify metabolites such as glutamate and GABA in the living human brain, which is one reason those chemicals have become such important targets in neuroscience. And meditation research has already produced striking long-term findings, including a 2016 Neuroimage study of 50 meditators and 50 controls that estimated the meditators’ brains were 7.5 years younger at age 50.

Taken together, those studies show why this latest blood work matters even if it is not the final word. It extends the conversation from mood and self-report into biology, while also reminding readers that the strongest claims still come from long-term practice, carefully matched controls, and repeated replication across different populations.

What this means for practice right now

For anyone in the mindfulness community, the practical takeaway is not to chase dopamine with a few sessions and expect a lab result. The more grounded reading is that meditation science is steadily building a picture of long-term practice as something that may be reflected in the body, including in neurotransmitter patterns, but only when the evidence comes from serious samples like these 30 experienced meditators and 30 controls.

So if you are weighing the value of your own practice, this study supports a patient view: the biochemical story of meditation is becoming more concrete, yet it is still a story about duration, depth, and lived discipline. The blood signal is real enough to keep researchers looking, but the lesson for practitioners is the same one the data keeps pointing back to, sustained practice matters more than a quick fix.